Quality Metrics for Stem Cell-Derived Cardiac Myocytes
Advances in stem cell manufacturing methods have made it possible to produce stem cell-derived cardiac myocytes at industrial scales for in vitro muscle physiology research purposes. Although FDA-mandated quality assurance metrics address safety issues in the manufacture of stem cell-based products,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2014-03-01
|
| Series: | Stem Cell Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213671114000320 |
| _version_ | 1828228385330954240 |
|---|---|
| author | Sean P. Sheehy Francesco Pasqualini Anna Grosberg Sung Jin Park Yvonne Aratyn-Schaus Kevin Kit Parker |
| author_facet | Sean P. Sheehy Francesco Pasqualini Anna Grosberg Sung Jin Park Yvonne Aratyn-Schaus Kevin Kit Parker |
| author_sort | Sean P. Sheehy |
| collection | DOAJ |
| description | Advances in stem cell manufacturing methods have made it possible to produce stem cell-derived cardiac myocytes at industrial scales for in vitro muscle physiology research purposes. Although FDA-mandated quality assurance metrics address safety issues in the manufacture of stem cell-based products, no standardized guidelines currently exist for the evaluation of stem cell-derived myocyte functionality. As a result, it is unclear whether the various stem cell-derived myocyte cell lines on the market perform similarly, or whether any of them accurately recapitulate the characteristics of native cardiac myocytes. We propose a multiparametric quality assessment rubric in which genetic, structural, electrophysiological, and contractile measurements are coupled with comparison against values for these measurements that are representative of the ventricular myocyte phenotype. We demonstrated this procedure using commercially available, mass-produced murine embryonic stem cell- and induced pluripotent stem cell-derived myocytes compared with a neonatal mouse ventricular myocyte target phenotype in coupled in vitro assays. |
| first_indexed | 2024-04-12T18:19:58Z |
| format | Article |
| id | doaj.art-aced2b184aca41c183079530ad865741 |
| institution | Directory Open Access Journal |
| issn | 2213-6711 |
| language | English |
| last_indexed | 2024-04-12T18:19:58Z |
| publishDate | 2014-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Stem Cell Reports |
| spelling | doaj.art-aced2b184aca41c183079530ad8657412022-12-22T03:21:30ZengElsevierStem Cell Reports2213-67112014-03-012328229410.1016/j.stemcr.2014.01.015Quality Metrics for Stem Cell-Derived Cardiac MyocytesSean P. Sheehy0Francesco Pasqualini1Anna Grosberg2Sung Jin Park3Yvonne Aratyn-Schaus4Kevin Kit Parker5Disease Biophysics Group, Wyss Institute for Biologically Inspired Engineering and School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USADisease Biophysics Group, Wyss Institute for Biologically Inspired Engineering and School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USADisease Biophysics Group, Wyss Institute for Biologically Inspired Engineering and School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USADisease Biophysics Group, Wyss Institute for Biologically Inspired Engineering and School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USADisease Biophysics Group, Wyss Institute for Biologically Inspired Engineering and School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USADisease Biophysics Group, Wyss Institute for Biologically Inspired Engineering and School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USAAdvances in stem cell manufacturing methods have made it possible to produce stem cell-derived cardiac myocytes at industrial scales for in vitro muscle physiology research purposes. Although FDA-mandated quality assurance metrics address safety issues in the manufacture of stem cell-based products, no standardized guidelines currently exist for the evaluation of stem cell-derived myocyte functionality. As a result, it is unclear whether the various stem cell-derived myocyte cell lines on the market perform similarly, or whether any of them accurately recapitulate the characteristics of native cardiac myocytes. We propose a multiparametric quality assessment rubric in which genetic, structural, electrophysiological, and contractile measurements are coupled with comparison against values for these measurements that are representative of the ventricular myocyte phenotype. We demonstrated this procedure using commercially available, mass-produced murine embryonic stem cell- and induced pluripotent stem cell-derived myocytes compared with a neonatal mouse ventricular myocyte target phenotype in coupled in vitro assays.http://www.sciencedirect.com/science/article/pii/S2213671114000320 |
| spellingShingle | Sean P. Sheehy Francesco Pasqualini Anna Grosberg Sung Jin Park Yvonne Aratyn-Schaus Kevin Kit Parker Quality Metrics for Stem Cell-Derived Cardiac Myocytes Stem Cell Reports |
| title | Quality Metrics for Stem Cell-Derived Cardiac Myocytes |
| title_full | Quality Metrics for Stem Cell-Derived Cardiac Myocytes |
| title_fullStr | Quality Metrics for Stem Cell-Derived Cardiac Myocytes |
| title_full_unstemmed | Quality Metrics for Stem Cell-Derived Cardiac Myocytes |
| title_short | Quality Metrics for Stem Cell-Derived Cardiac Myocytes |
| title_sort | quality metrics for stem cell derived cardiac myocytes |
| url | http://www.sciencedirect.com/science/article/pii/S2213671114000320 |
| work_keys_str_mv | AT seanpsheehy qualitymetricsforstemcellderivedcardiacmyocytes AT francescopasqualini qualitymetricsforstemcellderivedcardiacmyocytes AT annagrosberg qualitymetricsforstemcellderivedcardiacmyocytes AT sungjinpark qualitymetricsforstemcellderivedcardiacmyocytes AT yvonnearatynschaus qualitymetricsforstemcellderivedcardiacmyocytes AT kevinkitparker qualitymetricsforstemcellderivedcardiacmyocytes |